Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Votre recherche
Pays: France,Czech Republic,Spain,Sweden,Hungary,United Kingdom,Austria,Portugal,Poland,Italy
Trial Manager
MAJ Il y a 5 ans
Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis
To assess the efficacy of two different treatment regimens of etanercept in psoriasis subjects with psoriatic arthritis with respect to both the skin and joint manifestations.
Pays
Argentina
,
Australia
,
Austria
,
Belgium
,
Czech Republic
,
Denmark
,
Finland
,
France
,
Germany
,
Greece
,
Hungary
,
Italy
,
Korea, Republic of
,
Mexico
,
Netherlands
,
Poland
,
Portugal
,
Saudi Arabia
,
Serbia
,
Spain
,
Sweden
,
Switzerland
,
Taiwan, Province of China
,
Turkey
,
United Kingdom
,
Organes
Aucun
Spécialités
Aucun
Essai clos aux inclusions
Plus d'informations
nct
MAJ Il y a 5 ans
Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase
This study will assess the efficacy and safety of nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive/BCR-ABL positive chronic myeloid leukaemia in chronic phase. The aim of the study is to confirm the rates of complete molecular remission (CMR) of nilotinib in newly diagnosed CML chronic phase patients in a pan-European population using the EUTOS standardized laboratories.
Pays
Austria
,
Belgium
,
Bulgaria
,
Croatia
,
Czech Republic
,
Denmark
,
Estonia
,
Finland
,
France
,
Germany
,
Greece
,
Hungary
,
Italy
,
Latvia
,
Lithuania
,
Netherlands
,
Norway
,
Poland
,
Portugal
,
Romania
,
Slovakia
,
Slovenia
,
Spain
,
Sweden
,
Switzerland
,
United Kingdom
,
Organes
Aucun
Spécialités
Aucun
Essai clos aux inclusions
Plus d'informations
nct
MAJ Il y a 5 ans
The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
Patients will be randomised to receive either placebo or the study drug for a period of 30 weeks, in addition to their standard Parkinsonian medications. During the first 8 weeks, the patient's levodopa doses may be adjusted if necessary by the investigator. For the remainder of the 22 weeks, all medications should be kept stable. Patients will be required to attend the clinic twice during the screening period and then a further 8 times during the treatment period. They will be required to complete home diaries where they will record their motor function. In addition, their doctor will assess their Parkinson's disease during the clinic visits. There will also be blood draws for safety and pharmacokinetic and pharmacogenomics evaluation. Following the treatment and assessment period, they will return to the clinic one month later for follow up.
Pays
Austria
,
Belgium
,
Czech Republic
,
Estonia
,
France
,
Germany
,
Hungary
,
Israel
,
Italy
,
Lithuania
,
Poland
,
Portugal
,
Serbia
,
South Africa
,
Spain
,
Sweden
,
United Kingdom
,
Organes
Aucun
Spécialités
Aucun
Essai clos aux inclusions
Plus d'informations
1